451 randomized placebo - controlled double - blind multi - centre phase clinical trial 417 patients with hyperlipidemia (TG mmol L -1 ) were r

Size: px

Start display at page:

Download "451 randomized placebo - controlled double - blind multi - centre phase clinical trial 417 patients with hyperlipidemia (TG mmol L -1 ) were r"

镒颟牛
7 years ago
Views:

1 450 [ ] (2013) A 赵水平 1 陈雅琴 1 陈君柱 2 来江涛 2 ( ; ) [ ] A; ; ; ; ; ; [ ] 目的 A 方法 417 (TG) 2.3 ~ 6.5 mmol L -1 (n = 207) A (n = 210) 200 mg A 400 U TG (TC) (HDL- C) (LDL- C) A 结果 4 A TG 17.3% 31.6%; 8 A 23.8% 33.1% (P < 0.01) A HDL- C (P < 0.01) TC LDL- C (P > 0.05) A (P < 0.01) 结论 A TG TG A A [ ] R541.4 [ ] A Comparison of effects and safety of coenzyme A and fenofibrate in patients with dyslipidemia ZHAO Shui- ping 1 CHEN Ya- qin 1 CHEN Jun- zhu 2 LAI Jiang- tao 2 ( 1. Department of Cardiology the Second Xiangya Hospital Changsha HU - NAN China; 2. Department of Cardiology the First Hospital Attached to the Medical School of Zhejiang University Hangzhou ZHEJIANG China) [ KEY WORDS] acetyl - CoA; fenofibrate; dyslipidemia; hypertriglyceridemia; adverse drug reactions; randomized controlled trials; multicenter studies [ABSTRACT] AIM This study was designed to compare the effects and safety of coenzyme A (CoA) and fenofibrate on plasma lipid levels in the patients with dyslipidemia. METHODS In the prospective [ ] [ ] [ ] zhaosp@medmail.com.cn; aviva9903@yahoo.com.cn [ ]

2 451 randomized placebo - controlled double - blind multi - centre phase clinical trial 417 patients with hyperlipidemia (TG mmol L -1 ) were randomly divided into two groups and treated with CoA 400 U d -1 (n = 210) and fenofibrate 200 mg d -1 (n = 207) respectively for 8 weeks. After 4 weeks and 8 weeks blood routine urine routine hepatic and renal function blood glucose blood lipid and creatine kinase were measured. The primary end - point efficacy outcome is the TG lowing efficacy and the secondary efficacy parameters are variation rate of plasma total cholesterol ( TC) low- density lipoprotein cholesterol ( LDL- C) and high - density lipoprotein cholesterol ( HDL - C) and adverse events were compared after the treatment. RESULTS After the treatment for 4 weeks TG level reduce 31.6% and 17.3% respectively in the fenofibrate group and the CoA group. After the treatment for 8 weeks TG was significantly reduced 33.1% and 23.8% in two groups respectively. The difference between two groups was significantly ( P < 0.01). Compared with the fenofibrate group the increase of HDL- C in the CoA group was lower (P < 0.01). After the treatment there was no significant difference of LDL - C TC lowing rate between two groups. There were less drug - related adverse events in the CoA group than in the fenofibrate group and difference was significant. CONCLUSIONS It was showed that the TG lowing effect of fenofibrate 200 mg d -1 was better than CoA 400 U d -1. But CoA 400 U d -1 was with better safety and tolerance in the moderate dyslipidemia patients than fenofibrate. (TG) [1 2] TG 20% ~ 50% [3] TG [4] TG A 400 U d -1 TG : (1) 18 ~ [5 6] 75 ; (2) TG 2.3 ~ 6.5 mmol L -1 ; (3) A 48 h ; (5) A : 100 ; (3) BMI > 30 kg m -2 ; (4) : (ALT) ( ); (AST) 2 ; (5) : 200 mg : 179 μmol L -1 ; ( (6) ( 180 mmhg ) ; (4) (1) TC 7.0 mmol L -1 ; (2) 110 mmhg); (7) 1 2 ( 10.0 mmol L -1 ); (8) 2 ; (9)

3 452 ; (10) ; (11) (2) 0-1 ; (12) 0 6 ; (13) 3 (3) 4 ; (14) 12 h ; (15) HIV ; (16) (4) 8 ( ) 1 (7170A ; (17) ) TG TC HDL- C LDL- C ( ) ; (18) 3 ; (19) TG 20% 1 1. : TG 20%; TG 2. (20) ; (21) : ( 1) 4 8 TC LDL - C ; (22) HDL- C (2) ( ) TG 40% HDL- C > 0.1 mmol L -1 : (1) (TC-HDL- C) /HDL- C 20%; b. ; (2) TC 10% ~ 20% TG 20% ~ 40% HDL- ( C 0.1 ~ 0.26 mmol L -1 (TC-HDL- C) /HDL- C ); (3) ; (4) d. TC 10% TG 10% ; (5) HDL - C 0.1 mmol L -1 ( TC -HDL - C) / HDL- C 10% = ( + : (1) ) / 100% ; (2) ; (3) ; (4) ; 417 (n = ) A (n = ) 376 A 2 A ( 100 U); 2 1 (200 mg) 1 4 x ± s 4 : (1) -1 P < P < 0.05 (TC) TG (HDL- C) -20 : a. TC 20% 10% ~ 20%; c. ; ; ; SPSS l0.0 (LDL- C) LOCF ( last observation

4 453 carrying forward) 4 TG 0.70 mmol L -1 (PPS) 17.3%; mmol ( SS) L % 4 (ANCOVA) TG (P < 0.01) 8 TG (P > 0.05) (Lsmean) 95% (CI) 2 A 95%CI 95% 8 TG [ % CI CI 6% ( )] 95%CI 6% TG A TG A TG 3 3 (TC) (HDL- C) (LDL- C) A x ± s mmol L -1 TG TC LDL- C HDL- C A TG 4 TG 1.12 mmol L %; mmol L % A 2 A TG x ± s mmol L -1 n ± ± ± 1.39 c 2.20 ± ± 1.33 c A ± ± ± 1.50 cf 2.65 ± ± 1.46 cd t : c P < 0.01; d P > 0.05 f P < (n = 207) A (n = 210) TC 5.23 ± ± ± ± ± 0.86 a ± 0.85 ad 1 x ± s HDL- C 1.10 ± ± ± ± 0.24 A 0.12 ± 0.31 c 0.03 ± 0.29 af (n = 207) (n = 210) LDL- C 2.92 ± ± 0.87 / 54.3 ± ± ± ± ± 0.85 a ± 0.81 ad /kg m ± ± ± ± 2.6 /mmhg ± ± 12.8 /mmhg 79.5 ± ± 7.8 / min ± ± 7.6 / 46.9 ± ± 54.9 /mmol L ± ± 1.10 /mmol L ± ± 0.86 /mmol L ± ± 0.87 /mmol L ± ± 0.29 /mmol L ± ± 1.0 /U L ± ± 44.1 /U L ± ± 13.8 /U L ± ± 8.0 /mmol L ± ± 1.3 /μmol L ± ± 17.8 t : a P > 0.05 c P < 0.01; d P > 0.05 f P < 0.01 A 8 TC LDL- C (P > 0.05) HDL- C A (P < 0.01) 3 A % A 71.4%; % A 73.8% (P > 0.05) 4 χ 2 : P > n / (%) (79.3) A (84.0) (76.9) a (79.0) a CMH : a P > 0.05 A

5 (25.1%) 200 mg d -1 TC 40 (19.3%) 16 (7.7%); A 20 (9.5%) 5 (2.4%) 11 (5.2%) TG A TG (P < 0.01) ALT AST 8 (3.9%) 20 (9.7%) 3 ( 1.4% ) ; A ALT AST 1 A (0.5%) 3 (1.4%) 2 ALT AST 5 A 5 A ALT AST (n = 207) (n = 210) /U L ± ± ± ± ± c ± af /U L ± ± ± ± ± c 0.18 ± 9.09 af /mmol L ± ± ± ± ± 1.40 b 0.08 ± 1.40 ae /μmol L ± ± ± ± ± c ± af /mmol L ± ± ± ± ± 1.03 a ± 0.84 ad /U L ± ± ± ± ± a 0.55 ± ad t : a P > 0.05 b P < 0.05 c P < 0.01; d P > 0.05 e P < 0.05 f P < U d -1 A TG [1 2] TG A A LDL- C TG HDL- C LDL [10 11] LDL- C [12] [13 14] A A TG A A [6-8] A A b : A β- TG A TG A [9] TG A A 400 U TG

6 455 [ ] [1] MILLER M STONE NJ BALLANTYNE C et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association[J]. Circulation (20): [2] CHAPMAN MJ GINSBERG HN AMARENCO P et al. Triglyceride - rich lipoproteins and high - density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management[j]. Eur Heart J (11): [3] BARTER PJ RYE KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? [J]. Arterioscler Thromb Vasc Biol (1): [4] DAVIDSON MH ARMANI A McKENNEY JM et al. Safety considerations with fibrate therapy[j]. Am J Cardiol [7] McKEAGE K KEATING GM. Fenofibrate: a review of its use in dyslipidaemia[j]. Drugs (14): [8] JUN M FOOTE C LV J et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta- analysis [J]. Lancet (9729): [9]. A [J] (10): [10] CHAPMAN MJ REDFERN JS McGOVERN ME et al. Optimal pharmacotherapy to combat the atherogenic lipid triad [J]. Curr Opin Cardiol (5): [11] TONSTAD S DESPRES JP. Treatment of lipid disorders in obesity[j]. Expert Rev Cardiovasc Ther (8): [12] WIERZBICKI AS MORRELL J HEMSLEY D et al. The effect of fibrate- statin combination therapy on cardiovascular events: a retrospective cohort analysis[j]. Curr Med Res Opin (9): [13] ACCORD Study Group GINSBERG HN ELAM MB et al. (6A): 3C-18C. Effects of combination lipid therapy in Type 2 diabetes mellitus [5]. A [J]. N Engl J Med (17): [J] (5): [14] FRANSSEN R VERGEER M STROES ES et al. Combination [6]. A statin - fibrate therapy: safety aspects[j]. Diabetes Obes Metab [J] (1): (2): [ ] (2013) T 2 李锐钊 1 2 章斌 2 张丽 1 史伟 2 梁馨苓 2 刘双信 2 王文健 2 ( ; ) [ ] ; ; ; NFATC ; [ ] 目的 T 2 (NFAT2) 方法 NFAT2 11R- VIVIT NFAT2 ionomycin Western blot NFAT2 结果 NFAT2 20 mmol L -1 2 h NFAT2 ; Ionomycin NFAT2 (P > 0.05) 11R- VIVIT NFAT2 (P < 0.01) 11R- VIVIT (P > 0.05) 20 mmol L h [ ] [ ] [ ] ( ) [ ] @139.com [ ] shiwei.gd@139.com

405 急性心肌梗死是临床较为常见的心血管疾病, 病情危急, 病死率高 [1] 随着经皮冠状动脉介入治疗 (percutaneous coronary intervention,pci) 技术在急性心肌梗死急诊

405 急性心肌梗死是临床较为常见的心血管疾病, 病情危急, 病死率高 [1] 随着经皮冠状动脉介入治疗 (percutaneous coronary intervention,pci) 技术在急性心肌梗死急诊 404 冠心舒通胶囊预防急性心肌梗死 PCI 术后再狭窄的临床研究李静, 王建榜, 王西辉西安医学院第二附属医院心内科, 陕西西安 710038 摘要 : 目的研究冠心舒通胶囊预防急性心肌梗死经皮冠状动脉介入治疗 (PCI) 术后再狭窄的临床